ReviewDrug delivery2026
Artificial intelligence and extracellular vesicles in oncology: towards tumor diagnosis, prediction, and therapy.
Review in Drug delivery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Extracellular vesicles (EVs) have emerged as promising tools for early cancer detection, therapeutic monitoring, and drug delivery in oncology. Artificial intelligence (AI), particularly machine learning and deep learning, offers new analytical tools and computational approaches for EV research. This review summarizes recent advances in the application of AI to EV isolation, characterization, diagnosis, and drug delivery, with particular emphasis on its potential to enhance tumor detection sensitivity, diagnostic accuracy, and the rational design of delivery platforms. Special attention is given to the roles and recent applications of AI models in integrating multimodal features, characterizing EV heterogeneity, supporting diagnostic classification, and modeling in vivo behavior. Moreover, we examine the integration of AI with EV-based microfluidic isolation, surface-enhanced Raman spectroscopy (SERS), fluorescence imaging, and multiomics analysis. Among these areas, AI-assisted EV diagnostic applications are comparatively closer to clinical translation, with several studies incorporating patient-derived samples and AI-assisted diagnostic platforms, whereas AI-guided therapeutic EV design strategies remain largely exploratory. With the continued accumulation of multicenter, cross-platform EV datasets, improvements in algorithmic robustness, and closer integration of computational and experimental workflows, AI may support further clinical evaluation of EV-based diagnostics and the systematic optimization of therapeutic EV platforms.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.